ABSTRACT
Foram avaliadas taxas de gestação aos 15 dias e perda gestacional entre 15 e 60 dias em 430 transferências de embrião (TE) em éguas Mangalarga Marchador. Diagnósticos de gestação foram realizados entre 15 e 60 dias após TE. Para avaliar os efeitos da duração da fase folicular da receptora, foram formados três grupos: até três dias (<3d); quatro a seis dias (4-6d); sete ou mais dias (>7d). Para avaliar os efeitos do tamanho do folículo pré-ovulatório da receptora, foram formados outros três grupos: menor ou igual a 35mm (Ø<35); maior que 35 e menor ou igual a 45mm (35<Ø<45); maior que 45mm (Ø>45). Os grupos foram comparados pelo teste qui-quadrado (P<0,05). Quanto à duração da fase folicular, as taxas de gestação foram semelhantes (<3d - 83,1%; 4-6d - 86,4%; >d - 86,0%), e a perda gestacional maior em >7d (24,4%) que em <3d(12,0%) e 4-6d (13,3%), estas semelhantes entre si. Quanto ao tamanho folicular, as taxas de gestação foram semelhantes (Ø<35 - 86,4%; 35<Ø<45 - 86,5%; Ø>45 - 81,9%), assim como as de perda gestacional (Ø<35 - 13,2%; 35<Ø<45 - 18,1%; Ø>45 - 10,5%). Razões para a maior perda gestacional no grupo >7dnão foram esclarecidas, mas conclui-se que a duração da fase folicular pode ser fator de escolha de receptoras.
Pregnancy rates were evaluated at 15 days and pregnancy loss between 15 and 60 days on 430 embryo transfers (ET) in Mangalarga Marchador mares. Pregnancy diagnosis was performed between 15 and 60 days after ET. To evaluate the effects of the duration of the follicular phase of the recipient mare, three groups were formed: up to 3 days (<3d); 4 to 6 days (4-6d); 7 or more days (>7d). To evaluate the effects of the size of the pre-ovulatory follicle of the recipient mare, three other groups were formed: below or equal to 35mm (Ø<35); greater than 35 and below or equal to 45mm (35<Ø<45); greater than 45mm (Ø>45). The groups were compared by Chi-square test (P<0.05). Regarding the duration of the follicular phase, pregnancy rates were similar (<3d - 83.1%; 4-6d - 86.4%; >7d - 86.0%), and greater pregnancy loss in >7d (24.4%) than in <3d (12.0%) and 4-6d (13.3%), which were similar. Regarding the follicle size, pregnancy rates (Ø<35 - 86.4%; 35<Ø<45 - 86.5%; Ø>45 - 81.9%) and pregnancy loss (Ø<35 - 13.2%; 35<Ø<45 - 18.1%; Ø>45 - 10.5%) were similar. Reasons for the greatest pregnancy loss in the >7d group have not been elucidated, but we conclude that the duration of the follicular phase may be a factor for choosing recipient mares.
Subject(s)
Animals , Abortion, Veterinary , Embryo, Mammalian/embryology , Pregnancy/metabolism , Horses/classificationABSTRACT
This study was undertaken to evaluate an enzyme immunoassay (EIA) for hepatitis C virus antibody detection (anti-HCV), using just one antigen. Anti-HCV EIA was designed to detect anti-HCV IgG using on the solid-phase a recombinant C22 antigen localized at the N-terminal end of the core region of HCV genome, produced by BioMérieux. The serum samples diluted in phosphate buffer saline were added to wells coated with the C22, and incubated. After washings, the wells were loaded with conjugated anti-IgG, and read in a microtiter plate reader (492 nm). Serum samples of 145 patients were divided in two groups: a control group of 39 patients with non-C hepatitis (10 acute hepatitis A, 10 acute hepatitis B, 9 chronic hepatitis B, and 10 autoimmune hepatitis) and a study group consisting of 106 patients with chronic HCV hepatitis. In the study group all patients had anti-HCV detected by a commercially available EIA (Abbott(r)), specific for HCV structural and nonstructural polypeptides, alanine aminotransferase elevation or positive serum HCV-RNA detected by nested-PCR. They also had a liver biopsy compatible with chronic hepatitis. The test was positive in 101 of the 106 (95 percent) sera from patients in the study group and negative in 38 of the 39 (97 percent) sera from those in the control group, showing an accuracy of 96 percent. According to these results, our EIA could be used to detect anti-HCV in the serum of patients infected with hepatitis C virus.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Genome, Viral , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C Antibodies/isolation & purification , Recombinant Proteins , Viral Core Proteins/immunology , Alanine Transaminase/blood , Enzyme-Linked Immunosorbent Assay , Hepatitis C Antibodies/blood , Hepatitis C, Chronic/diagnosis , Immunoenzyme Techniques/methods , Immunoglobulin G/isolation & purification , Polymerase Chain Reaction , RNA/bloodABSTRACT
Estudos recentes têm demostrado eficácia do extrato de um vegetal, o Phyllanthus amarus, no tratamento dos portadores crônicos do vírus da hepatite B. Por tratar-se de substância facilmente encontrada em nosso meio e pela ausência de publicaçöes sobre seu uso para esta virose, na literatura nacional, revisäo do assunto foi realizada. Entretanto, os bons resultados referidos nao têm sido repetidos por alguns pesquisadores e, até o momento, a análise dos dados disponíveis revela controvérsias. Falhas metodológicas nesses protocolos, seja com respeito aos critérios de inclusäo, seja na discussäo dos resultados, poderiam explicar a situaçäo do problema. Conclui-se que novos estudos deveräo ser conduzidos, até que se possa estabelecer o real papel do Phyllanthus amarus no tratamento dos portadores crônicos do vírus de hepatite B.